β3 adrenergic receptor as potential therapeutic target in ADPKD

Autosomal dominant polycystic kidney disease (ADPKD) disrupts renal parenchyma through progressive expansion of fluid‐filled cysts. The only approved pharmacotherapy for ADKPD involves the blockade of the vasopressin type 2 receptor (V2R). V2R is a GPCR expressed by a subset of renal tubular cells a...

Descripción completa

Detalles Bibliográficos
Autores principales: Schena, Giorgia, Carmosino, Monica, Chiurlia, Samantha, Onuchic, Laura, Mastropasqua, Mauro, Maiorano, Eugenio, Schena, Francesco P., Caplan, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531837/
https://www.ncbi.nlm.nih.gov/pubmed/34676684
http://dx.doi.org/10.14814/phy2.15058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531837/
https://www.ncbi.nlm.nih.gov/pubmed/34676684
http://dx.doi.org/10.14814/phy2.15058

Ejemplares similares